SYDNEY, AUSTRALIA--(Marketwired - May 1, 2016) - Prima BioMed Ltd (
This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3 rd of October 2028.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au .
For further information please contact: U.S. Investors: Mr Matthew Beck The Trout Group LLC +1 (646) 378-2933 mbeck@troutgroup.com Australia Investor/Media: Mr Matthew Gregorowski Citadel-MAGNUS +61 2 8234 0100 mgregorowski@citadelmagnus.com